A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects wth Diagnosed Atopic Dermatitis

Grants and Contracts Details

StatusFinished
Effective start/end date12/1/06 → 12/30/15

Funding

  • Bavarian Nordic: $64,495.00